Compositions and Methods for Using Human YKL-40 to Treat Acute Lung Injury
AssigneeYale University
InventorJack A. Elias
Life of this patent
Estimating the term…
Abstract
The invention includes methods of treating oxidant-mediated acute lung injury in a subject by administration of a chitinase-like protein molecule, or an activator thereof. The invention also includes methods of assessing the level of a chitinase-like protein molecule in a subject as a marker of the prognosis of a subject suffering from acute lung injury.
Claims20
A method of treating acute lung injury in a subject, said method comprising administering an effective amount of a chitinase-like protein molecule, or activator thereof, to said subject, thereby treating said acute lung injury.
A method of preventing acute lung injury in a subject, said method comprising administering an effective amount of a chitinase-like protein molecule, or activator thereof, to said subject, thereby preventing said acute lung injury.
A method of determining the severity of acute lung injury in a subject, the method comprising:
- a. obtaining a sample from the subject, wherein the subject has, or is suspected of having, acute lung injury,
- b. determining in the sample the level of at least one chitinase-like protein molecule,
- c. comparing the level of the at least one chitinase-like protein molecule in the sample with the level in a control or reference standard, wherein the difference in the level of the at least one chitinase-like protein molecule between the sample and the control or reference standard is a measure of the severity of acute lung injury in the subject.
A method of evaluating the progression of acute lung injury in a subject, the method comprising:
- a. obtaining a sample from the subject, wherein the subject has, or is suspected of having, acute lung injury,
- b. determining in the sample the level of at least one chitinase-like protein molecule,
- c. comparing the level of the at least one chitinase-like protein molecule in the sample with the level in a control or reference standard at a first time point,
- d. comparing the level of the at least one chitinase-like protein molecule in the sample with the level in a control or reference standard at a second time point, wherein the difference in the level of the at least one chitinase-like protein molecule between the sample and the control or reference standard at the first time point and the second time point is a measure of the progression of acute lung injury in the subject.
A method of evaluating the effect of a treatment of acute lung injury in a subject, the method comprising:
- a. obtaining a sample from the subject, wherein the subject has, or is suspected of having, acute lung injury,
- b. determining in the sample the level of at least one chitinase-like protein molecule,
- c. comparing the level of the at least one chitinase-like protein molecule in the sample with the level in a control or reference standard before treatment,
- d. comparing the level of the at least one chitinase-like protein molecule in the sample with the level in a control or reference standard after treatment, wherein the difference in the level of the at least one chitinase-like protein molecule between the sample and the control or reference standard before treatment and after treatment is a measure of the effect of the treatment of acute lung injury on the subject.
Dependencies are inferred from the claim text.